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Abstract 
Objectives: The aim of this study was to investigate, using quantitative sensory testing 
(QST) parameters and the painDETECT (PD-Q) screening questionnaire, the presence of 
neuropathic pain (NeP) in subjects with unilateral painful cervical radiculopathy 
(CxRAD) and in subjects with unilateral non-specific neck-arm pain associated with 
heightened nerve mechanosensitivity (NSNAP). Methods: All subjects completed the 
PD-Q prior to QST. QST was performed bilaterally in the maximal pain area and the 
affected dermatome in 23 subjects with painful C6 or C7 radiculopathy and 8 subjects 
with NSNAP following a C6/7 dermatomal pain distribution. Results: Subjects with 
CxRAD demonstrated a significant loss of sensory function in mechanical (p ≤ 0.021) 
and vibration sense (p ≤ 0.003) on the symptomatic side compared to the asymptomatic 
side in both tested body regions and in the dermatome reduced cold detection (p = 0.021) 
and pressure pain sensitivity (p = 0.005), findings consistent with nerve root damage. 
These sensory alterations in the maximal pain area/symptomatic side are confirmative for 
the presence of NeP. In contrast to these QST data, only 30% of subjects with CxRAD 
demonstrated a NeP component according to the PD-Q score. In subjects with NSNAP, a 
significant side-to-side difference was demonstrated for warm detection threshold in the 
dermatome (p = 0.030). The PD-Q score indicated that NeP components were unlikely in 
this group. Discussion: QST data suggest that NeP is likely to be observed in subjects 
with painful CxRAD, but not in subjects with NSNAP.  
 




Nerve-related neck-arm pain disorders are heterogeneous with clinical signs and 
symptoms and pattern of pain and sensory abnormalities varying widely between 
individuals. While a neuropathic mechanism is commonly implied in disorders such as 
painful cervical radiculopathy (CxRAD)1, patients are likely to present with a mix of 
nociceptive and neuropathic pain (NeP), more commonly referred to as a mixed pain 
syndrome2-7. Both NeP and mixed pain sydnromes can be intense forms of pain, and 
patients with these disorders are characterised by impaired physical and mental quality of 
life and a substantial level of disability, leading to increased health care costs compared 
to patients with nociceptive pain5,6,8. Characterisation of these patients with respect to the 
‘pain mix’, and the possible dominance of one pain type in mixed pain syndromes is of 
therapeutic relevance9, as NeP in particular requires targeted management.  
 
This study investigated two samples of subjects with nerve-related neck-arm pain: 
subjects with painful CxRAD and subjects with non-specific neck-arm pain (no clinical 
signs of radiculopathy) associated with heightened nerve mechanosensitivity (NSNAP). 
Heightened nerve mechanosensitivity is defined as pain in response to upper limb 
movement that causes nerve elongation10. This condition can present as a discrete 
disorder without any signs of nerve damage such as sensory or motor loss10,11. Subjects 
with CxRAD and NSNAP may demonstrate similar pain characteristics such as pain with 
or without negative/positive sensory symptoms, however the mix of NeP and nociceptive 
pain may vary and has not yet been defined in these groups.  
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Quantitative sensory testing (QST) has been recommended for accurate sensory profiling 
in the assessment of patients with NeP12. A side-to-side comparison of QST data within 
patient groups is recommended13,14, as patients may present with subtle sensory 
alterations not identifiable by comparison to reference data. To date, only one study 
investigated sensory abnormalities in patients with CxRAD15, however QST 
measurements were not taken from the patient’s maximal pain area, as is required for the 
assessment of NeP components12,16. No study, to our knowledge, has established the QST 
profile of patients with NSNAP comparable to our cohort.  
 
Further, the use of NeP screening tools for identification of NeP components has been 
recommended12. The painDETECT (PD-Q)17, a validated self reported NeP screening 
tool, has increasingly been employed for the identification of NeP in patients with low 
back and leg pain17-20, however, its usefulness in the screening of NeP in patients with 
neck-arm pain has not been reported. 
 
The purpose of this study was to investigate, using QST and the PD-Q, the presence of 
NeP components in subjects with CxRAD and subjects with NSNAP. We hypothesized 
that: 
1. For subjects with CxRAD, there would be a significant side-to-side difference in 
QST parameters between the symptomatic and asymptomatic side.  
2. For subjects with NSNAP, there would be no significant side-to-side difference in 
QST parameters between the symptomatic and asymptomatic side.  
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3. There would be no difference in the PD-Q score between subjects with CxRAD 
and subjects with NSNAP. 
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MATERIALS AND METHODS 
Subjects 
Subjects were recruited as part of another concurrent study21. For inclusion into the study, 
all subjects were required to fulfil the inclusion criteria of unilateral neck pain and arm 
pain/paraesthesia in a C6/7 distribution, symptom duration of 3 to 18 months and current 
pain intensity ≥ 2 on a visual analogue scale (VAS). Subjects with CxRAD were required 
to demonstrate signs of either C6 or C7 nerve root dysfunction with neurological deficits 
consistent with the affected nerve root level and with compressive radiculopathy (either 
absent or diminished reflexes and/or myotomal weakness and dermatomal sensory 
deficits of light touch and/or vibration sense). Additionally, subjects were required to 
have a demonstrable clinically relevant abnormality on imaging studies16,22 that indicated 
compromise of the exiting nerve root at the relevant spinal level. Inclusion criteria for 
subjects with NSNAP were no clinical signs of radiculopathy and evidence of increased 
peripheral nerve sensitivity to mechanical stimuli10, including pain in response to a nerve 
provocation test in the upper limb (NPTMEDIAN)10. Exclusion criteria for both groups 
were: evidence of a metabolic or a medical disease; other neurological or psychiatric 
disease; a history of cardiovascular disease; and an insufficient level of English. Subjects 
had to be able to understand the PD-Q questions and independently complete the PD-Q. 
Specifically, subjects had to be able to understand the instructions and requirements for 
the QST procedures and be able to give a reliable response that did not depend on 
translation. Subjects were not screened for the presence of depression or anxiety.  
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Prior to participation, all subjects were examined by a highly qualified Musculoskeletal 
Physiotherapist (Master qualification) who had extensive clinical experience within a 
tertiary pain medicine unit in triaging patients with suspected nerve lesions and 
associated NeP to ascertain they met the inclusion criteria (BT). The assessment included 
the subject’s history, pain drawings, pain description for their neck and for their arm pain 
and pain behaviours, musculoskeletal and neurological examination and review of reports 
of diagnostic tests (imaging, nerve conduction studies). The diagnostic classification of 
both participating groups was verified by a Fellowship-trained spinal Neurosurgeon (GL) 
and a Fellowship–qualified (Fellow of the Australian College of Physiotherapists) 
Specialist in Musculoskeletal Physiotherapy (TH), both of whom were blinded to the 
clinician’s subject classification. Each Fellow independently reviewed the subjects’ notes 
and the results of any medical investigations. Only subjects whose clinical presentation 
was confirmed by all three examiners were included in the data analyses (see Fig. 1).  
 
Subjects were recruited from private clinics and physiotherapy, pain management and 
neurosurgery departments at five local metropolitan hospitals in Perth, Western Australia, 
and from the local community via radio and newspaper advertising (see flow chart of 
recruitment Fig.1). All referrals of patients with neck/upper limb symptoms to the 
neurosurgery triage clinic received between September 2007 and November 2010 were 
reviewed by the investigator (author BT). Patients in whom the referral indicated the 
possible presence of a unilateral nerve lesion/disease were selected and were clinically 
examined. The study protocol and recruitment procedures were approved by the local 
Ethics Committees of all participating institutions and adhered to the ethical guidelines of 
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the Declaration of Helsinki. All subjects were asked to sign an informed consent form 
prior to participation. 
 
Questionnaire 
A battery of questionnaires was used to clinically characterise the subject groups and to 
incorporate the multidimensional aspects of pain as proposed by the IMMPACT 
guidelines23. This battery was administered immediately before the QST. The instructions 
given on the questionnaires were the instructions consistent with the standardized 
instruments. All subjects completed the short form-36 health questionnaire (SF-36v2®)24 
to assess health-related quality of life. The Hospital Anxiety and Depression Scale 
(HADS)25 was used to screen for anxiety and depression, with two outcome scores 
generated, each with a maximum score of 21 for each parameter. Scores of ≤ 10 for each 
are considered within normal range. Sleep quality over the last week was recorded on a 
100-cm VAS with the end points 0 cm (good sleep) and 10 cm (bad sleep)26. In addition, 
to assess fear avoidance behaviours, subjects completed the Tampa Scale of 
Kinesiophobia (TSK)27. This questionnaire contains 17 items that relate to fear of 
movement and fear of (re) injury. A score ≥ 40 is considered to indicate significant 
kinesiophobia28. The Neck Disability Index (NDI)29 was used to assess the level of 
subject disability. It is a well-validated ten-item questionnaire30,31. Scores of < 4 indicate 
no disability, 5 – 14 mild disability, 15 – 25 moderate disability, 25 – 34 severe disability, 
and > 35 complete disability29. 
 
The PD-Q17 consists of one descriptor relating to temporal and one to spatial pain 
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characteristics and of seven weighted sensory descriptors. These sensory descriptors 
relate to the main pain area that a person records on the body chart of PD-Q17. The lowest 
weight for each descriptor is 0, indicating that the person does not experience the relevant 
sensation, and the highest weight is 5, indicating the sensation is felt very strongly. PD-Q 
classifies patients into three groups, defined by Freynhagen et al17 as follow: the result is 
negative = a NeP component is unlikely (score 0 – 12), the result is unclear = the result is 
ambiguous, however a NeP component can be present (score 13 – 18), or the result is 
positive = a NeP is likely (score 19 – 38). The strongest and average pain intensity over 
the last four weeks was recorded on a numeric rating scale (NRS) (0 = no pain, 10 = 
maximum pain) as part of the PD-Q17. Subjects were not given any specific instructions 
on how to complete the PD-Q other than the instructions given on the questionnaire. 
 
Quantitative sensory testing 
The standardised QST protocol of the German Research Network on Neuropathic Pain 
(DFNS) was employed using the same equipment and standardised instructions as 
outlined by Rolke et al.14,32 The test battery comprised the following assessments: cold 
and warm detection thresholds (CDT, WDT); the number of paradoxical heat sensations 
(PHS) during the procedure of alternating warm and cold stimuli (thermal sensory limen 
(TSL)); cold and heat pain thresholds (CPT, HPT); mechanical detection threshold 
(MDT); mechanical pain threshold (MPT); stimulus-response functions: mechanical pain 
sensitivity (MPS) and dynamic mechanical allodynia (DMA); wind-up ratio (WUR); 
vibration detection threshold (VDT) and pressure pain threshold (PPT).  
 
11 
QST was performed over the maximal pain area, as indicated by the subjects and the 
corresponding contralateral mirror side. In subjects with CxRAD, additional testing was 
conducted in the exact dermatomal area of sensory loss as determined during clinical 
examination, and for subjects with NSNAP in the area of distal paraesthesia or pain, plus 
in the contralateral side for both groups. While the QST in the dermatome does not give 
information about the presence of NeP components16, it does assist to further characterise 
each subject group and to detect possible sensory alterations that may be indicative of a 
nerve root lesion. Testing was conducted by one investigator (BT) in a laboratory with a 
constant room temperature. The investigator was blind to the results of the PD-Q as the 
questionnaire was scored after the QST testing. As the clinical examination of subjects 
and QST testing were not performed on the same day, the key inclusion criteria for each 
group (for CxRAD: signs of nerve root dysfunction, for NSNAP absence of nerve root 
dysfunction and presence of heightened nerve mechanosensitivity) were reassessed prior 
to QST. Subjects were asked not to take any analgesics on the day of testing. A sample 
size calculation, based on QST data by Rolke et al14, estimated that a sample of 25 in 
each subject group was needed to detect clinically significant differences between the 
symptomatic and asymptomatic arm. 
 
Nerve provocation test (NPTMEDIAN) 
The NPTMEDIAN was performed after the QST as described previously11. The range of 
elbow extension was measured with an electro-goniometer (SG110, Biometrics Ltd, 
United Kingdom). The subject was asked to press an external trigger at the first onset of 
pain or at the increase of their resting pain (P1) if present, and at a second time point 
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when the subject reached their pain tolerance (P2) for this movement. Elbow extension 
was performed to the end of joint range or to P2, whichever occurred first. The 
NPTMEDIAN was performed three times on each side and the mean value of three 
recordings of P1 and P2 was used for analysis. Subjects who did not report consistently 
an onset of P1 or P2 in all three trials (i.e. they reported an onset in only 1 or 2 trials) 
were excluded from the analysis (P1 asymptomatic side n = 3). Four subjects with 
CxRAD could not be tested due to high pain levels and the associated potential for 
exacerbation of their condition. 
 
Statistical analysis 
SPSS version 17 was used for all analyses. All data were analysed for their distribution 
properties (Shapiro-Wilk test). An independent T-test was used to compare symptom 
duration, pain intensity, sleep quality, the NDI, TSK and PD-Q scores between subject 
groups. Anxiety and depression scores and the physical and mental component summary 
scores of the SF-36 were compared using the Mann-Whitney-U Test.  
 
The QST variables HPT and VDT were normally distributed. All other QST data were 
normally distributed in log-space and were log-transformed prior to statistical analysis32. 
Within each group, QST data were compared between sides using a paired T-test. For 
subjects with CxRAD, a side-to-side comparison was also performed for two subgroups, 
based on imaging results: (i) subjects with nerve root compression due to a disc 
protrusion/herniation (n = 14), and (ii) subjects with nerve root compression due to 
osteophytic stenosis (n = 7). Responses to the NPTMEDIAN were compared using 
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Wilcoxon Signed Ranks Test, as data were not normally distributed. Significance was 




Twenty-three subjects with painful C6 or C7 CxRAD (8 female; mean age 46.3 ± 9.6 
years) and 8 subjects with NSNAP following a C6/C7 dermatomal distribution (7 female; 
mean age 45.1 ± 14.9 years) participated in the study. Eleven subjects presented with a 
C6 radiculopathy and 12 subjects with a C7 radiculopathy. Their maximal pain areas 
were as follows: upper trapezius muscle n = 4; paravertebral cervical spine n = 2; 
paravertebral thoracic spine n = 7; above and below spine scapula n = 2; upper arm n = 5; 
forearm n = 2; just above the elbow n = 1. All subjects with CxRAD had undergone 
medical imaging (Computed tomography (CT) n = 1; Magnetic Resonance Imaging 
(MRI) n = 22). Based on the imaging findings, 7 subjects demonstrated nerve root 
compression due to osteophytic stenosis, 2 subjects due to a disc/osteophytic complex 
and 14 subjects due to a disc protrusion/herniation. One subject with NSNAP presented 
with pain in a C6 dermatomal distribution and 7 subjects with pain in a C7 dermatomal 
distribution. Six patients reported the upper trapezius muscle as their maximal pain area, 
and 2 patients the paravertebral thoracic spine. Only two subjects with NSNAP had 
medical imaging (CT) performed of the cervical spine. In these two subjects, CT did not 
demonstrate any abnormality indicating compromise of a nerve root at the relevant spinal 
level. 
 
Table 1 presents demographic data of all subjects. The independent T-test showed no 
significant differences between subject groups in age, symptom duration, pain intensities, 
fear avoidance behaviour and scores on the NDI. NDI scores reflected moderate 
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disability for patients with CxRAD and mild disability for patients with NSNAP. There 
were no significant differences between subject groups physical and mental components 
of the SF-36 and anxiety and depression scores (Mann-Whitney-U Test). The anxiety 
scores were within the normal range in over 75% of patients and the depression scores in 
over 91% of patients. Subjects with CxRAD had a significantly higher score on the PD-Q 
compared to subjects with NSNAP (independent T-test: p = 0.038). Seven subjects (30%) 
with CxRAD reported a score of ≥ 19, indicating the ‘likely’ presence of NeP and one 
subject (12.5%) with NSNAP scored ≥ 19. A larger proportion of subjects with CxRAD 
were on pain medication compared to the group with NSNAP. 
 
The subjects’ self-reported pain descriptors for their neck and arm pain obtained during 
the clinical examination are documented in Table 2. Both groups demonstrated clinical 
signs of heightened nerve mechanosensitivity in the symptomatic arm, indicated by a 
significant side-to-side difference in the range of motion of elbow extension deficit at the 
onset of P1 (p < 0.03) and P2 (p < 0.013) between arms (Fig. 2) (Wilcoxon Signed Ranks 
Test). In both groups, the pain onsets occurred much earlier in range in the symptomatic 
arm compared to the asymptomatic arm. 
 
Side-to-side comparison in subjects with CxRAD 
For subjects with CxRAD, in the maximal pain area vibration and mechanical detection 
sense were significantly reduced on the symptomatic side compared to the asymptomatic 
side (paired T-test: VDT: p = 0.003; MDT: p = 0.021) (Table 3). Side-to-side 
comparisons of all other QST parameters in the maximal pain area were not significant. 
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In the dermatome, there was a loss of function on the symptomatic side in cold detection 
(CDT: p = 0.021), mechanical detection (MDT: p = < 0.001), vibration detection (VDT: p 
= 0.001) and pressure pain sensitivity (PPT: p = 0.005) (Table 4). There were no side-to-
side differences in any other QST parameters. Reports of DMA and PHS were infrequent. 
One subject with CxRAD demonstrated DMA bilaterally in the maximal pain area and on 
the symptomatic side in the dermatome. PHS was reported by one subject once in the 
maximal pain area on the symptomatic side, and by a different subject once on the 
asymptomatic side. Two subjects reported PHS once on the asymptomatic side of the 
dermatome. Individual QST data are presented in Table 5 (Supplemental Digital Content 
1). One subject appeared to present with only one sensory alteration in the maximal pain 
area on the symptomatic side. All other subjects seemed to demonstrate two or more 
sensory alterations on the symptomatic side. Eleven subjects demonstrated cold 
hyperalgesia (≥ 15°)33 on the symptomatic side, and in five of these subjects cold 
hyperalgesia occurred bilaterally. Some subjects presented with reduced pressure 
sensitivity in their main pain area, while others presented with increased pressure 
sensitivity. 
 
Subjects with nerve root compression due to osteophytic stenosis (n = 7) demonstrated a 
loss of function on the symptomatic side of the maximal pain area in warm detection 
(WDT: p = 0.034), TSL (p = 0.010), vibration detection (VDT: p = 0.007) and pressure 
sensitivity (PPT: p = 0.029), and a loss of function in the symptomatic dermatome in cold 
detection (CDT: p = 0.007), mechanical (MDT: p = 0.003) and vibration detection (VDT: 
p = 0.032) compared to the asymptomatic side (paired T-test). Subjects with nerve root 
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compression due to a disc protrusion/herniation (n = 14) demonstrated reduced 
mechanical detection sense on the symptomatic side in the maximal pain area (MDT: p = 
0.013) and reduced mechanical and vibration sense and pressure sensitivity in the 
symptomatic dermatome (MDT: p <0.001; VDT: p = 0.004; PPT: p = 0.006) (paired T-
test). 
 
Side-to-side comparison in subjects with NSNAP 
In subjects with NSNAP, in the maximal pain area, there was no side-to-side difference 
in any QST parameter (Table 3; paired T-test). In the dermatome, the side-to-side 
comparison demonstrated a significant loss of function on the symptomatic side in WDT 
(p = 0.030) (Table 4). No other side-to-side comparisons were statistically different. No 
subject with NSNAP demonstrated DMA in any body region. PHS was reported by one 
subject twice on the symptomatic side in the maximal pain area. Individual QST data are 
presented in Table 6 (Supplemental Digital Content 2). Three subjects demonstrated more 
than one sensory alteration in their maximal pain area on the symptomatic side (subject 3, 
4, 5). Three subjects (subject 1, 4, 8) demonstrated bilateral cold hyperalgesia.  
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DISCUSSION 
This study investigated differences in QST parameters between symptomatic and 
asymptomatic sides and the presence of NeP components in subjects with painful 
CxRAD and subjects with NSNAP, using QST and the PD-Q. The subject groups 
demonstrated similar clinical profiles, as indicated by their psychometric data, but the 
dominant pain type differed between groups. In subjects with CxRAD, QST findings 
demonstrated a significant loss of function mediated by non-nociceptive sensory fibers in 
the painful innervation territory of the affected nerve root on the symptomatic side 
compared to the asymptomatic side, findings consistent with the characteristics of NeP12. 
The PD-Q identified 30% of subjects with CxRAD demonstrating the likely presence of 
NeP. In subjects with NSNAP, the absence of significant side-to-side differences in any 
QST parameters in the maximal pain area and the results of PD-Q suggest that NeP 
components were unlikely.  
 
Subjects with CxRAD demonstrated significant side-to-side differences in mechanical 
and vibration detection in their maximal pain area, the symptomatic side being less 
sensitive to the stimuli than the control side. The hypoaesthesia on the symptomatic side 
is consistent with a loss of function due to nerve root damage and with the presence of 
NeP16, and consistent with both findings in patients with peripheral nerve injury34-36 and 
for patients with segmental post-surgical NeP34. Furthermore, almost all subjects with 
CxRAD demonstrated 2 or more sensory alterations in their maximal pain area. It has 
been reported that the frequency of sensory aberrations tends to increase with the 
likelihood of the presence of NeP37. The significant loss in the affected dermatome of 
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cold, mechanical and vibration detection and pressure sensitivity, also support the 
presence of a nerve root lesion. The loss of cold detection is comparable with findings in 
affected dermatomes of patients with cervical15 and lumbar radiculopathy38-42 and the loss 
of mechanical and vibration detection has also been reported in the affected dermatomes 
of patients with lumbar radiculopathy38.  
 
QST data in CxRAD is scarce, with only one study profiling this patient group15, and 
findings demonstrated bilateral cold and pressure pain hypersensitivity in the cervical 
spine area. Comparison of our data to these findings is however limited, as the majority 
of our subjects did not have their maximal pain area in the cervical spine, furthermore the 
cervical spine area tested in the Chien et al study15 did not necessarily reflect the maximal 
pain area of these patients. On a group level, our subjects with CxRAD did not 
demonstrate cold hypersensitivity compared to the asymptomatic side, however 
individual QST data revealed that 48% of our subjects presented with cold hyperalgesia. 
Cold hyperalgesia is a common sequel of peripheral nerve injury 35,43-45, but it can also 
occur in the absence of nerve damage and in the absence of pain, as documented in 
patients with painless peripheral nerve injuries35,44 and in patients with depression 
without pain46. Bilateral cold hyperalgesia, as seen in some of our subjects with CxRAD, 
was also observed in individuals with painful and painless peripheral nerve injuries44. 
Mechanisms underlying cold hypersensitivity are still not fully understood and likely 
include both central47-49 and peripheral nervous system mechanisms50-52. 
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In contrast to patients with for example peripheral nerve injury demonstrating mechanical 
hyperalgesia44,53,54, such a positive sensory sign was not a dominant feature in our 
subjects with CxRAD. Increased pressure sensitivity was observed in some individuals 
with CxRAD, however others demonstrated reduced pressure sensitivity. Similar pressure 
pain dichotomy has also been documented in individuals with peripheral nerve 
injury44.The variances between individual subjects indicates the likely presence of sub-
groups with differing somatosensory profiles within our cohort, similar to somatosensory 
profiles reported for patients with lumbar radiculopathy55 and for patients with peripheral 
NeP 53,54. Somatosensory heterogeneity within a clinical disorder may account for 
differing individual responses to pharmaceutical interventions, as seen in clinical trials of 
patients with lumbar and cervical radiculopathies56,57.  
 
Furthermore, we found differing sensory profiles between groups depending on the 
cervical imaging findings. The subject group with mechanical nerve root compression 
due to osteophytic stenosis demonstrated a loss of small and large sensory fiber function 
in the symptomatic maximal pain area, whereas a loss of only large sensory fiber function 
occurred in the disc herniation group. It is unclear why these differences in sensory 
phenotypes occurred, and studies with larger sample sizes are required to further attest 
these findings. Our data highlight the need for individual patient examination including 
clinical history as well as clinical examination, screening for NeP and the presence of 
psychological factors and imaging if appropriate. This approach is required in order to 
make a more fully informed clinical decision re the sensory profile and how that may link 
with targeted management. For example, a patient characterised by increased pain 
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sensitivity may require specific behavioural and cognitive management, possibly 
different pain medication and appropriate physical intervention such as pacing strategies 
compared to a patient without heightened pain sensitivity. 
 
According to the recently proposed diagnostic grading system of certainty for the 
presence of NeP16, on a group level our cohort with CxRAD demonstrated definite NeP, 
however this does not exclude the simultaneous presence of nociceptive pain. Other 
structures (e.g. joints, discs, muscles) are likely involved in contributing to nociceptive 
input and potentially impacting the total “pain experience”. Fourteen subjects (61%) 
indicated the neck/trapezius/scapula/thoracic area as their main area of pain which 
correlates with specific cervical nerve root pain distributions58, but is also a common area 
for musculoskeletal pain and referred somatic pain59. Coexisting musculoskeletal 
disorders are common in patients with suspected cervical radiculopathy60 and nociceptive 
pain may be located in the same area as the innervation territory of the affected nerve 
structure. This consideration might complicate the interpretation of sensory aberrations, 
as sensory changes can be present in non-NeP conditions61-64. 
 
In our current study, the likely presence of mixed pain3 is reflected in the PD-Q scores 
and the self-volunteered pain descriptors. Subjects used self-reported pain descriptors 
commonly identified for NeP65, some of these matching the descriptors used in PD-Q, but 
subjects also used descriptors commonly identified for nociceptive pain66. The fact that 
30% of our radiculopathy cohort reported a score of ≥ 19, and 65% reported a score ≥ 16, 
may suggest that on a theoretical continuum between ‘dominantly nociceptive’ and 
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‘dominantly  neuropathic’ pain67, some of these subjects’ sensory profiles were 
characterised dominantly by NeP components compared with nociceptive pain.  
 
Subjects with NSNAP did not demonstrate any side differences in QST parameters in 
their maximal pain area. Hence, based on the pain distribution and history this subject 
group would be classified as having ‘possible’ NeP16. However, some individuals did 
present with sensory alterations in their maximal pain area (bilateral cold hyperalgesia, 
apparent reduced vibration sense). It stands debatable if these sensory aberrations are 
indicative of NeP, as such sensory changes have also been reported in non-NeP 
conditions61-64. Hence, clinical judgement based on the findings of a comprehensive 
clinical examination, including the assessment of neural and musculoskeletal structures 
and other organ systems, is crucial for the determination of underlying pain types. 
 
With the exception of reduced warm detection in the symptomatic arm, where the 
difference between sides was < 1º and of doubtful clinical significance, we did not find 
any side differences for QST parameters in the dermatome in subjects with NSNAP. The 
interpretation of what entails a clinically significant difference for thermal detection 
thresholds is inconsistent14,36,44,68. Based on clinical judgment, some authors consider a 
side difference of ≥ ± 1º as pathological36, others argue a side difference ± 1º is within 
normal range14,68. More normative data from various body regions are required to attest 
these statements.  
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The QST findings in our subjects with NSNAP do not suggest the presence of NeP 
components and on the whole this is in accordance with the PD-Q score in this group, 
with the exception of one individual who scored >19. This person may have been an 
outlier with a maximum score (5) for the presence of a burning sensation and tingling and 
a high score (4) for the presence of numbness in her pain area. The weighing of the pain 
descriptor item of PD-Q may lead to skewing of the final score of PD-Q towards the 
presence of NeP. Apart from the descriptors for the presence of paraesthesia being used 
by all subjects, a minority of subjects used self-reported pain descriptors common to NeP. 
 
The main characteristic for this group was the side-to-side difference in pain response to 
the NPTMEDIAN, consistent with a heightened pain response in the symptomatic arm. Our 
results suggest that the clinical presentation of heightened nerve mechanosensitivity as a 
discrete disorder should not equate with the presence of a NeP component. This subject 
group with NSNAP did not meet the new definition of NeP, i.e. “pain caused by a lesion 
or disease of the somatosensory nervous system”69 as the combination of clinical 
examination findings, QST data and available diagnostic tests did not provide evidence 
for the presence of a nerve lesion. Heightened nerve mechanosensitivity can coexist with 
nerve lesions and NeP, as demonstrated in our subjects with CxRAD and another patient 
group15. In fact, heightened nerve mechanosensitivity in the lower limb, as identified by 
the straight leg raise test, was reported to be part of a cluster of physical examination 
discriminative indicators for NeP in lumbar radiculopathy70. However the role of 
heightened nerve mechanosenstivity as discriminative factor for NeP in patients with 
CxRAD has not yet been determined. 
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The PD-Q17 was specifically designed to identify NeP components in patients with low 
back pain with and without referred pain, and therefore it was anticipated that the 
questionnaire could be transferable to patients with neck-arm pain. However, the PD-Q17 
identified only 30% of subjects with cervical radiculopathy as having NeP. This 
seemingly lowered capability of PD-Q to identify NeP compared to the sensitivity of 
85% in the original validation study17 may be related to a mismatch between the pain 
descriptors reported by the subjects and the pain descriptors included in PD-Q. For 
example, sensitivity to light touch was not a dominant feature in our radiculopathy 
cohort, consistent with findings in patients with lumbar radiculopathy55, and similarly 
cold and pressure sensitivity and burning pain were only present in some individuals. 
Using PD-Q, Mahn et al55 identified one sub-group of patients with radicular leg pain 
presenting with only one dominant sensory descriptor contained in the PD-Q55. The PD-
Q had been originally validated in a dichotomous patient sample (NeP/nociceptive pain) 
and patients with mixed pain presentations were excluded17. Splitting patients into two 
categories may limit the ability to generalise results to a mixed pain clinical population. It 
remains unclear if the discrepancy in performance of the PD-Q in our study and in the 
original validation study17 relates to variations in patient cohorts, as specific patient 
characteristics were not reported in the original study17. 
 
Another possible explanation for the lowered sensitivity of PD-Q may be the weighing of 
the item descriptors. In a study of patients with spinal cord injuries71, cut-off levels for 
discriminating NeP were low in the weighted items of PD-Q and it was suggested that the 
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intensity of the sensory descriptor may not be that important for discrimination, but 
simply its presence or absence. Summarized our findings suggest that the PD-Q may not 
be suitable for the identification of NeP in subjects with cervical radiculopathy and mixed 
pain. 
 
The strength of our study lies in the robust methods, including a complete examination 
(clinical and standardized QST) of patients with CxRAD and patients with NSNAP and 
using tight inclusion/exclusion criteria. While the latter was chosen to ensure our groups 
were homogeneous, the strict inclusion criteria brought with them the compromise of 
obtaining smaller sample sizes than anticipated and also limit the generalisability of our 
findings. The sample size of our subject group with NSNAP was modest and this might 
limit the power to demonstrate significant side-to-side differences. Despite extensive 
recruitment efforts over the period of three years, we were not able to recruit more 
subjects fulfilling the criteria for NSNAP inclusion. Based on our recruitment strategy, 
and given the fact that many subjects were recruited from a neurosurgery triage clinic, the 
prevalence of the discrete disorder of NSNAP would appear to be low. Only anecdotal 
data exist on the prevalence of this condition. A further limitation of the study lies in the 
non-blinding of the investigator performing the QST testing and future research would be 
strengthened by a design that incorporated blinding. 
 
In conclusion, although subjects with CxRAD and subjects with NSNAP had 
commonalities in their clinical pain pattern and clinical profile, the dominant pain type 
differed between subject groups, as indicated by the specific QST profiles and associated 
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responses to the PD-Q. NeP was more common in subjects with CxRAD, whereas 
subjects with NSNAP were characterised by predominantly nociceptive pain components. 
The variability of sensory profiles between individuals within one subject group 
highlights the importance of individual assessment for the identification of NeP 
components for patients with mixed pain syndromes. The PD-Q seemed unsuitable for 
the identification of NeP in our subjects with CxRAD and should not be used as a 
surrogate for clinical examination. Our somatosensory profiles for these clinical groups 
may assist clinicians in targeting more specific management for these patients and 
reinforces the importance of skilled clinical examination in making clinical management 
decisions for patients with suspected NeP. 
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FIGURE 1. Flow chart of recruitment of subjects with cervical radiculopathy (CxRAD) and subjects with non-specific neck-arm pain 
associated with heightened nerve mechanosensitivity (NSNAP)
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FIGURE 2. Elbow extension ROM deficit at onset of pain (P1) and at the  
limitation of movement due to pain (P2) in the symptomatic (sympt) and asymptomatic 
(asympt) arm in subjects with cervical radiculopathy (CxRAD) (A) and subjects with 
non-specific neck-arm pain with associated heightened nerve mechanosensitivity 
(NSNAP) (B). Data are presented as medians with (25th and 75th percentiles).  
*Significant difference between sides (p < 0.05) 
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TABLE 1. Demographics and clinical profiles of subjects with cervical radiculopathy  
(CxRAD) and subjects with non-specific neck-arm pain associated with heightened nerve 
mechanosensitivity (NSNAP). 
 CxRAD 
(n = 23) 
NSNAP 
(n = 8) 
p 
 
Age (years)* 46.3 (9.6) 45.1 (14.9) 0.833 
Gender (female, n) 8 7  
Symptom duration (months)* 7.6 (4.1) 8.1 (3.0) 0.766 
Maximal pain intensity during last 4 
weeks (NRS 0-10)* 
7.2 (2.2) 7.6 (0.6) 0.686 
Average pain intensity during last 4 weeks  
(NRS 0-10)* 
5.0 (2.1) 5.1 (0.6) 0.914 
Sleep quality during last week (VAS)*  5.3 (2.7) 5.9 (2.2) 0.591 
Hospital Anxiety and Depression Scale  
Anxiety score (HADS)# 6.0 (4.0; 9.0) 8.0 (6.2; 10.5) 0.295 
Within normal range (≤ 10), n  21(91%) 6 (75%)  
Depression score (HADS)# 3.0 (2.0; 6.0) 3.5 (1.2; 6.7) 0.982 
Within normal range (≤ 10), n  21 (91%) 8 (100%)  
SF-36    
Physical Component# 40.6 (33.9; 46.6) 46.4 (41.2; 53.2) 0.121 
Mental Component# 52.3 (39.1; 56.6) 48.4 (32.1; 52.7) 0.187 
Neck Disability Index* 16.2 (7.7) 13.4 (5.9) 0.351 
39 
Tampa Scale of Kinesiophobia* 40.9 (8.1) 36.7 (7.5) 0.211 
painDETECT* 17 (5) 12 (6) 0.038 
Negative: NeP component unlikely, n 2 (9%) 4 (50%)  
Unclear: result ambigious, n 14 (61%) 3 (37%)  
Positive: NeP component likely, n 7 (30%) 1 (12%)  
Subjects with medication, n  15 (65.2%) 3 (37.5%)  
Current medication◊    
Selective serotonin reuptake inhibitor, n  1 (4.3%) 1 (12.5%)  
Serotonin-norepinephrine reuptake 
inhibitor, n 
2 (8.7%)   
Tricyclic antidepressant, n 1 (4.3%)   
Antiepileptics, n 2 (8.7%)   
Opioids, n 4 (17.4%)   
Benzodiazepine, n 2 (8.7%)   
Analgesics, n 7 (30.4%) 1 (12.5%)  
Non-steroidal anti-inflammatories, n 7 (30.4%) 2 (25%)  




TABLE 2. Distribution of pain descriptors volunteered during the clinical 
examination by subjects with cervical radiculopathy (CxRAD) and subjects 
with non-specific neck-arm pain associated with heightened nerve 
mechanosensitivity (NSNAP) for their neck pain and arm pain. Data are expressed 
in number of subjects (n) and (%)*. 
 CxRAD 
(n = 23) 
NSNAP 
(n = 8) 
 Neck pain Arm pain Neck pain Arm pain 
Constant, n 17 (74%) 11 (48%) 5 (62%) 3 (38%) 
Intermittent, n 6 (26%) 12 (52%) 3 (38%) 5 (62%) 




Pins and needles, n 








Burning, n 6 (26%) 7 (30%) 5 (62%) 2 (25%) 
Shooting, n  5 (22%)  2 (25%) 
Electric shock, n 1 (4%) 3 (13%)   
Nerve pain, n    2 (25%) 
Dead, n  3 (13%)  2 (25%) 
Numbish, n 1 (4%)  1 (12%)  
Ache, n 10 (43%) 6 (26%) 3 (37%) 1 (12%) 
41 
Dull, n 7 (30%) 4 (17%)   
Sharp, n 6 (26%) 3 (13%) 1 (12%)  
Heavy, n  2 (9%)   
Deep, n 2 (9%) 2 (9%) 1 (12%) 2 (25%) 
Pain, n 2 (9%) 3 (13%)   
Sore, n 1 (4%)  2 (25%)  
Muscle pain, n 1 (4%)    
Throbbing, n 1 (4%)    
*The percentages do not add to 100% as some patients used several descriptors to 
describe their pain. 
◊Descriptor obtained through specific questioning  
Common descriptors for neuropathic pain are highlighted in grey.  
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TABLE 3. QST parameters are shown for the maximal pain area in the asymptomatic and symptomatic  
sides of subjects with cervical radiculopathy (CxRAD) and subjects with non-specific neck-arm pain  
associated with heightened nerve mechanosensitivity (NSNAP). Data are shown as mean for untransformed  
data (HPT, VDT) (± standard deviation) and retransformed mean for log-normally distributed data. 
  Maximal pain area 
QST Parameter Group Asymptomatic side Symptomatic side p 
CDT (°C) CxRAD 1.86 1.89 0.912 
 NSNAP 1.12 1.16 0.787 
WDT (°C) CxRAD 3.45 3.83 0.288 
 NSNAP 2.28 2.64 0.439 
TSL (°C) CxRAD 5.51 6.22 0.180 
 NSNAP 3.94 4.17 0.615 
CPT (°C) CxRAD 9.10 11.16 0.084 
 NSNAP 10.50 12.16 0.273 
43 
HPT (°C) CxRAD 45.9 (± 3.7) 45.4 (± 4.4) 0.489 
 NSNAP 45.3 (± 2.3) 45.1 (± 2.2) 0.801 
MDT (mN) CxRAD 2.10 3.79 0.021 
 NSNAP 1.57 1.37 0.608 
MPT (mN) CxRAD 23.75 29.85 0.351 
 NSNAP 19.87 28.10 0.351 
MPS (NRS100) CxRAD 0.53 0.45 0.338 
 NSNAP 1.01 0.77 0.171 
WUR (ratio) CxRAD 2.68a 2.81a 0.855 
 NSNAP 2.49 2.98 0.486 
VDT (x/8) CxRAD 5.9 (± 0.9) 5.4 (± 1.1) 0.003 
 NSNAP 5.2 (± 0.4) 5.2 (± 1.0) 0.835 
PPT (kPa) CxRAD 434 403 0.346 
 NSNAP 366 390 0.496 
an = 18 
CDT: cold detection threshold; WDT: warm detection threshold; TSL: thermal sensory limen;  
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CPT: cold pain threshold; HPT: heat pain threshold; MDT: mechanical detection threshold;  
MPT: mechanical pain threshold; MPS: mechanical pain sensitivity; WUR: wind-up ratio;  
VDT: vibration detection threshold; PPT: pressure pain threshold. 
 
45 
TABLE 4. QST parameters are shown for the dermatome in the asymptomatic and symptomatic  
sides of subjects with cervical radiculopathy (CxRAD) and subjects with non-specific neck-arm pain  
associated with heightened nerve mechanosensitivity (NSNAP). Data are shown as mean for untransformed  
data (HPT, VDT) (± standard deviation) and retransformed mean for log-normally distributed data. 
  Dermatome 
QST Parameter Group Asymptomatic side Symptomatic side p 
CDT (°C) CxRAD 2.12 2.68 0.021 
 NSNAP 1.43 1.55 0.439 
WDT (°C) CxRAD 3.43 4.17 0.119 
 NSNAP 2.25 3.14 0.030 
TSL (°C) CxRAD 6.15 6.87 0.258 
 NSNAP 4.2 5.11 0.116 
CPT (°C) CxRAD 7.56 8.08 0.649 
 NSNAP 8.4 7.80 0.721 
46 
HPT (°C) CxRAD 45.6 (± 3.5) 46.1 (± 3.8) 0.565 
 NSNAP 46.2 (± 3.1) 46.4 (± 2.2) 0.736 
MDT (mN) CxRAD 1.18 4.53 <0.001 
 NSNAP 2.26 2.65 0.682 
MPT (mN) CxRAD 70.91 84.45 0.467 
 NSNAP 36.13 34.90 0.868 
MPS (NRS100) CxRAD 0.39 0.34 0.453 
 NSNAP 0.84 0.74 0.391 
WUR (ratio) CxRAD 2.01a 2.45a 0.340 
 NSNAP 2.04 2.15 0.633 
VDT (x/8) CxRAD 7.0 (± 0.8) 6.2 (± 1.0) 0.001 
 NSNAP 6.6 (± 1.2) 6.6 (± 1.4) 0.893 
PPT (kPa) CxRAD 492 572 0.005 
 NSNAP 405 417 0.260 
an = 14 
CDT: cold detection threshold; WDT: warm detection threshold; TSL: thermal sensory limen;  
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CPT: cold pain threshold; HPT: heat pain threshold; MDT: mechanical detection threshold;  
MPT: mechanical pain threshold; MPS: mechanical pain sensitivity; WUR: wind-up ratio;  
VDT: vibration detection threshold; PPT: pressure pain threshold. 
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SUPPLEMENTAL DIGITAL CONTENT 1 TABLE 5. Individual QST parameters of subjects with CxRAD in the maximal pain 
area 






















1a Scapula asymp 17 0.6 3.7 4.3 28.8 40.6 5.66 17.15 2.64 1.24 4.50 154 
  symp  0.6 2.5 3.6 29.6 39.5 6.50 8.57 1.22 3.08 5.83 148 
2a Thoracic  asymp 17 0.9 2.0 3.0 9.3 43.1 2.64 27.86 0.26 2.50 5.33 353 
  symp  1.0 2.7 3.4 5.0 44.4 2.46 9.85 0.23 2.20 4.83 344 
3b Cervical asymp 16 5.4 6.7 8.7 6.6 49.2 9.85 51.98 0.38 2.13 6.50 449 
  symp  1.4 5.8 9.8 27.5 46.2 6.96 64.00 0.17 2.20 6.17 290 
4a Thoracic asymp 19 0.8 3.0 4.1 9.0 45. 1.23 137.19 0.01  6.50 1022 
  symp  1.3 2.9 3.6 7.2 44.7 2.00 194.01 0.03  6.17 1041 
5b Upper arm asymp 16 0.8 4.5 6.1 19.8 47.8 2.83 103.97 0.03  6.33 538 
  symp  2.7 5.2 11.5 23.8 49.8 16.00 25.99 0.02  4.67 487 
6a Upper arm asymp 23 1.7 2.8 4.3 5.0 48.5 2.83 11.31 0.70 3.57 5.33 627 
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  symp  2.9 4.7 7.1 5.0 46.8 18.38 25.99 0.46 2.50 4.50 275 
7b Upper trap asymp 15 0.7 1.4 2.2 5.0 47.4 1.32 18.38 0.01  4.50 286 
  symp  0.8 1.9 2.6 7.5 46.8 0.93 29.86 0.04  4.00 162 
8b Cervical asymp 25 4.3 3.3 8.7 5.0 49.5 1.41 51.98 0.93 3.40 5.33 486 
  symp  4.0 5.0 9.9 5.2 45.9 3.48 477.71 0.23 2.67 4.50 338 
9a Upper arm asymp 17 6.3 3.1 5.5 5.9 42.2 1.23 6.06 19.27 1.19 6.83 259 
  symp  2.3 2.9 4.7 24.9 38.8 2.14 6.06 8.56 0.95 5.67 438 
10b Upper trap asymp 13 2.8 3.2 7.4 7.8 48.2 2.46 238.86 0.00 2.00 5.83 839 
  symp  1.5 3.9 8.5 15.5 47.6 12.13 222.86 0.07 2.74 5.17 747 
11b Thoracic asymp 14 1.4 3.1 5.4 5.0 48.9 1.62 45.25 0.21 5.25 6.50 882 
  symp  1.4 4.2 7.1 5.0 48.8 0.23 11.31 0.47 2.64 6.17 987 
12c Upper trap asymp 7 0.8 3.5 6.8 14.3 43.8 4.00 51.98 1.33 2.64 5.83 448 
  symp  2.2 5.0 7.9 22.7 45.9 8.00 84.45 1.11 4.40 5.83 610 
13a Thoracic asymp 25 2.3 5.6 7.5 11.4 48.6 2.46 21.11 0.49 3.60 6.17 408 
  symp  1.6 2.7 2.9 28.6 36.6 0.38 13.93 1.13 2.40 6.33 181 
50 
14c Upper trap asymp 16 1.2 2.0 3.3 19.1 44.5 0.35 12.13 0.86 4.40 7.83 248 
  symp  3.4 6.9 10.8 8.1 48.7 0.47 294.07 0.12 5.00 7.83 246 
15a Thoracic asymp 14 1.7 2.6 3.7 27.5 37.6 0.19 9.19 0.43 6.86 6.17 470 
  symp  2.20 3.1 5.1 25.5 38.8 0.22 6.50 0.66 6.33 5.00 546 
16a Scapula asymp 16 1.2 5.4 7.1 5.0 49.2 1.00 17.15 0.24 1.89 5.67 654 
  symp  1.3 3.0 4.4 5.0 49.7 2.30 14.93 0.08 0.83 5.67 809 
17a Upper arm asymp 8 3.9 4.2 6.1 5.0 48.6 0.50 25.99 0.00  5.83 546 
  symp  4.9 2.9 6.7 5.0 49.4 1.41 8.00 0.01  5.33 558 
18b Thoracic asymp 21 2.2 3.4 4.4 27.2 37.8 22.63 5.66 0.23 4.00 5.67 378 
  symp  2.6 3.8 6.2 24.5 44.9 12.13 7.46 0.19 4.33 4.17 285 
19a Elbow asymp 27 2.4 2.8 4.1 18.3 43.5 1.23 11.31 2.54 1.50 6.33 222 
  symp  1.6 2.5 3.5 26.3 36.6 9.19 22.63 2.85 3.14 6.17 163 
20a Forearm asymp 16 5.8 3.8 5.7 5.0 46.9 11.31 12.13 0.13  4.17 387 
  symp  2.3 5.2 9.4 5.0 49.9 32.00 22.63 1.34 5.00 2.50 621 
21a Thoracic asymp 14 3.2 12.9 19.3 5.0 50.0 6.96 9.85 0.10 6.67 6.33 564 
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  symp  7.7 6.8 14.3 5.0 50.0 32.00 9.85 0.11 5.00 6.33 679 
22a Forearm asymp 26 1.2 2.2 5.5 8.6 50.0 4.29 64.00 0.49 1.57 7.50 573 
  symp  0.9 3.4 6.2 17.6 49.3 45.25 724.08 0.00  6.00 869 
23a Upper arm asymp 13 3.6 3.8 7.8 5.0 45.5 0.66 6.50 3.13 1.64 5.00 262 
  symp  1.4 7.4 10.5 5.0 44.8 3.03 7.46 2.06 1.82 5.33 205 
Subj: subject; PD-Q: painDETECT score; Scapula: above or below spine scapula; Thoracic: paravertebral thoracic spine; Cervical: 
paravertebral cervical spine; Upper trap: upper trapezius muscle; asympt: asymptomatic; sympt: symptomatic 
CDT: cold detection threshold; WDT: warm detection threshold; TSL: thermal sensory limen; CPT: cold pain threshold; HPT: heat 
pain threshold; MDT: mechanical detection threshold; MPT: mechanical pain threshold; MPS: mechanical pain sensitivity; WUR: 
wind-up ratio; VDT: vibration detection threshold; PPT: pressure pain threshold. 
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1 Thoracic 14 asymp 1.5 3.6 6.9 27.9 43.1 0.44 68.59 1.94 1.63 5 428 
   symp 1.1 4.0 8.5 29.0 44.6 0.54 64.00 1.10 3.15 5.67 452 
2 Upper trap 16 asymp 0.7 3.2 4.2 14.1 45.4 13.93 13.93 0.62 1.26 5.50 454 
   symp 1.0 4.3 5.1 13.3 44.5 4.29 14.93 1.17 1.50 6 441 
3 Upper trap 18 asymp 4.4 3.6 9.8 5.8 48.5 24.25 13.00 2.88 1.67 4.67 396 
   symp 2.2 3.1 5.3 11.0 42.0 42.22 137.19 1.18 1.43 3.83 330 
4 Upper trap 7 asymp 0.7 0.6 2.6 16.4 41.6 1.32 17.15 2.56 2.47 4.50 226 
   symp 0.8 2.3 3.0 25.3 44.1 2.00 8.00 2.12 2.63 4.67 428 
5 Thoracic 21 asymp 0.8 2.2 2.5 5.0 46.5 0.81 32.00 0.07 1.50 5.33 503 
   symp 1.0 3.2 3.5 5.0 47.4 1.32 51.98 0.11 6.00 5.50 572 
6 Upper trap 10 asymp 0.7 1.8 2.8 6.0 44.3 0.47 27.86 0.61 3.56 5.50 195 
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   symp 1.2 1.5 3.7 10.0 42.9 0.20 84.45 0.37 5.00 6.83 178 
7 Upper trap 5 asymp 1.2 3.2 3.9 5.0 47.6 0.38 8.57 0.96 1.86 5.50 494 
   symp 1.2 2.3 3.9 5.4 46.7 0.50 6.96 0.86 2.29 4.33 466 
8 Upper trap 8 asymp 1.2 2.4 2.9 26.0 45.8 1.32 14.93 0.63 15.00 5.33 385 
   symp 1.3 1.7 2.7 16.7 48.3 0.47 12.13 0.21 5.08 5.00 405 
Subj: subject; PD-Q: painDETECT score; Thoracic: paravertebral thoracic spine; Upper trap: upper trapezius muscle; asympt: 
asymptomatic; sympt: symptomatic. 
CDT: cold detection threshold; WDT: warm detection threshold; TSL: thermal sensory limen; CPT: cold pain threshold; HPT: heat 
pain threshold; MDT: mechanical detection threshold; MPT: mechanical pain threshold; MPS: mechanical pain sensitivity; WUR: 
wind-up ratio; VDT: vibration detection threshold; PPT: pressure pain threshold. 
           Gain of function relative to asymptomatic side                Loss of function relative to asymptomatic side
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